{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-057927","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2024-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.254388+00:00","generated_at":"2026-06-02T04:05:58.975018+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Revelation Biosciences Q1 net loss $2.7M; cash $14.6M sufficient through 2024","bullets":["Net loss of $2.7M ($2.46 per share) for Q1 2024, compared to net earnings of $6.2M in Q1 2023, driven by change in warrant liability.","Cash and cash equivalents $14.6M as of March 31, 2024, up from $12.0M at December 31, 2023.","Net cash used in operating activities was $2.8M, up from $1.6M YoY, due to clinical study expenses for GEM-AKI and GEM-SSI.","Company believes current cash is sufficient to fund operations through 2024 based on current projections."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-057927","json":"https://secwatch.observer/filing/0000950170-24-057927.json","markdown":"https://secwatch.observer/filing/0000950170-24-057927.md","text":"https://secwatch.observer/filing/0000950170-24-057927.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000095017024057927/0000950170-24-057927-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000095017024057927/revb-20240510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T04:05:58.975018+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"31d3caf70a3cc4594457f73328844a3b2d90df18","claim":"REVELATION BIOSCIENCES, INC. reported the three months ended March 31, 2024 results: net income $2.7 million, EPS $2.46 basic and diluted net loss per share.","evidence_excerpt":"Revelation’s net loss for the three months ended March 31, 2024 was $2.7 million, or $2.46 basic and diluted net loss per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000095017024057927/0000950170-24-057927-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Net income","value":"$2.7 million"},{"label":"EPS","value":"$2.46 basic and diluted net loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}